• EAN 2023
    EAN 2023
    9th Congress - Budapest 2023, July 1-4

    Highlights From EAN 2023

    Ofatumumab presentations

    Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis
    Ofatumumab, interferon ß1 and glatiramer acetate as first-line treatment in everyday practice: the AIOLOS study
    Five-Year Efficacy Outcomes of Ofatumumab in Relapsing MS Patients: Insights From ALITHIOS Open-label Extension Study
    Effect of Longer-term Ofatumumab Treatment on Disability Worsening and Brain Volume Change

    Multiple Sclerosis

     

     

    BE2309299374